Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer.

Trial Profile

Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inodiftagene-vixteplasmid (Primary)
  • Indications Carcinoma; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Anchiano Therapeutics; BioCancell Therapeutics

Most Recent Events

  • 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 13 Mar 2012 Results from this trial show that primary endpoint has been met and signs of efficacy observed at 240 mg dose. BioCancell is acting to expand the trial at highest dosage group.
  • 06 Feb 2012 Additional lead trial investigator (Ronnie Shapira-Frommer) identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top